Navigation Links
Haemonetics Reports Third Quarter of Fiscal 11
Date:1/31/2011

operating income$81,654$79,184Restructuring, deal integration and closing costs6,598450Contingent consideration income(1,894)-Non-GAAP operating income $86,358$79,634Non-GAAP income before taxesGAAP income before taxes$81,510$77,382Restructuring, deal integration and closing costs6,598450Contingent consideration income(1,894)-Non-GAAP income before taxes$86,214$77,832Non-GAAP net incomeGAAP net income$58,992$54,409Restructuring, deal integration and closing costs6,598450Contingent consideration income(1,894)-Tax benefit associated with non-GAAP items(1,939)(110)Non-GAAP net income$61,757$54,749Non-GAAP net income per common share assuming dilutionGAAP net income per common share assuming dilution$2.32$2.08Non-GAAP items after tax per common share assuming dilution$0.11$0.02Non-GAAP net income per common share assuming dilution$2.42$2.10Presented below are additional Constant Currency performance measures.  We measure different components of our business at constant currency.  We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates.  These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of $1.20 per Euro, and 110 Yen to the $1.00.  They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.  Non-GAAP revenuesGAAP revenue$506,661$476,326Foreign currency effects(29,788)(30,481)Non-GAAP revenue - constant currency$476,873$445,845Non-GAAP net incomeNon-GAAP net income, adjusted for restructuring and deal integration costs and contingent consideration income$61,757$54,749Foreign currency effects(12,589)(15,711)Income tax associated with foreign currency effects3,5764,798Non-GAAP net income - constant currency52,74443,836Non-GAAP net income per common share assuming dilutionNon-GAAP net income per commo
'/>"/>
SOURCE Haemonetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
2. Neogen Reports 33% Increase in Net Income
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. New Topical Patent Research Reports Recently Published at MarketPublishers.com
5. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
6. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
7. GeneLink Reports Third Quarter Results
8. Imagenetix, Inc. Reports Second Quarter 2011 Results
9. Transgenomic Reports Third Quarter Financial Results
10. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 News ... India devoted to genome-based research for ... Genomics (NIBMG) is taking a bite out of oral ... among males in India with the ... solutions from DataDirect Networks (DDN). , To fuel its ...
(Date:9/23/2014)... , Sept. 23, 2014   GenoSpace , ... comprehensive suite of tools to enable the broad use ... announced that it has been awarded Phase I of ... from the National Institutes of Health (NIH) to enable ... Logo - http://photos.prnewswire.com/prnh/20140922/147649 ...
(Date:9/23/2014)... Dr. Williams says, “Find The Black Box ... a three phase process that can lead to the ... would go far beyond anything previously imagined. First everyone ... healthcare.” , “Every effort to improve the quality of ... progress throughout that system because all of the experts ...
(Date:9/22/2014)... who were treated with a statin in the hospital ... likely to survive than those who were not, according ... . This study was conducted by the same researchers ... can improve survival in victims of ischemic stroke., Ischemic ... a blood vessel that blocks blood from reaching areas ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2
... of Allowance of European Patent Application Covering Its Core Natural ... Applications Protection Rights to All Cytokine ... ... (GO), a biotechnology,company dedicated to the discovery and development of improved ...
... 24 Researchers at 28th annual,National Academy ... City this,weekend will present data to help ... breast cancer survivors affected by,"Chemobrain". Chemobrain is ... types of cancer. It is associated with ...
... 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX:ONY), a ... products for the treatment of cancer, today,announced that ... scheduled to present at the 7th Annual BIO ... 2008 at 8:00 a.m. Pacific Time., A ...
Cached Biology Technology:GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 2GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 3GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 4Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From 'Chemobrain' 2
(Date:9/23/2014)... a lot greener thanks to a novel technique developed ... solar energy to accelerate tailings pond reclamation efforts by ... light source to treat oil sands process affected water ... and James Bolton have found that using the sunlight ... as efficiently but at a much lower cost. , ...
(Date:9/23/2014)... The National Institutes of Health will award funds to ... Drug Screening program to improve ways of predicting drug ... to refine existing 3-D human tissue chips and combine ... complex functions of the human body. Led by the ... will support 11 institutions at $17 million in 2014 ...
(Date:9/23/2014)... Company has secured $21 million in a Series C ... the Company,s cancer immunotherapy pipeline and advance its lead ... the round, with participation from Majuven and all existing ... Harbinger Venture Capital. , Eureka is engaged in ... mimic the functions of a T cell receptor, a ...
Breaking Biology News(10 mins):Solar energy-driven process could revolutionize oil sands tailings reclamation 2NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4
... This release is available in German . ... disk currently consists of about 3 million magnetic atoms. Researchers ... memory with one bit per molecule. By an electric pulse, ... magnetic state and a low-conductive, non-magnetic state. This novel correlation ...
... in most developing countries to meet the United Nations, ... from hunger by 2015 compared with 1990 levels, according ... and weight, published today in the Lancet . ... improved overall since 1985, one in five infants and ...
... medicine for Parkinson,s disease, by investigating signs of the ... respond to drug treatments. The study was funded by ... skin cells from patients with genetically inherited forms of ... found that neurons derived from individuals with distinct types ...
Cached Biology News:Nature: Molecule changes magnetism and conductance 2Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates 2Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates 3Patient-derived stem cells could improve drug research for Parkinson's 2Patient-derived stem cells could improve drug research for Parkinson's 3Patient-derived stem cells could improve drug research for Parkinson's 4
...
Recalibration of HL-2000-CAL products...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Biology Products: